Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132510 | 0.88 | PDE4D (0.44) | HRH3PDE7APDE4DUSP2 | |
| SCHEMBL6132560 | 0.87 | PDE4D (0.48) | HRH3PDE7APDE4DUSP2MAPT | |
| SCHEMBL6374773 | 0.87 | USP2 (0.43) | HRH3PDE7APDE4DUSP2 | |
| SCHEMBL6376063 | 0.86 | PDE4D (0.46) | HRH3GPR119PDE7APDE4DUSP2 | |
| SCHEMBL6135316 | 0.83 | HRH3 (0.52) | HRH3GPR119MAPT | |
| SCHEMBL3103265 | 0.83 | ALDH1A1 (0.34) | HRH3USP2MAPTSMN1; SMN2 | |
| SCHEMBL3103272 | 0.83 | ALDH1A1 (0.34) | HRH3USP2MAPTSMN1; SMN2 | |
| SCHEMBL6132812 | 0.82 | HRH3 (0.38) | HRH3PDE7APDE4DUSP2 | |
| SCHEMBL6133752 | 0.81 | MEN1 (0.39) | HRH3GPR119 | |
| SCHEMBL6133750 | 0.81 | MEN1 (0.39) | HRH3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004014-A1 | Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004014-A1 | Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals | MAN2B1, MAN2A1, MANBA | HRH3 2668/4885GPR119 385/4885PDE7A 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.